Pfizer invests in Valneva, updates agreement on Lyme disease vaccine
![Photo: Mark Lennihan/AP/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14163155.ece/ALTERNATES/schema-16_9/21036612288333-6000x3378ma.jpg)
Back in 2020, Valneva and US-based Pfizer partnered up on the development of the French firm’s vaccine candidate, VLA15, for Lyme disease, also known as Lyme borreliosis.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
EU to terminate vaccine agreement with Valneva
For subscribers